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Apoptotic cell suicide can be initiated by a plethora of
stimuli that generally feed into one of two known cell
death signaling pathways (Fig. 1; for review see references 1
and 2). Both pathways share many features, including mo-
lecular devices that spark caspase activation by proenzyme
recruitment, oligomerization, and proximity-induced auto-
catalytic activation. Beyond this, however, their activities
are relatively (but not absolutely) distinct. The ‘intrinsic’
pathway feeds cell death signals through the mitochon-
drion, which appears to act as a generic damage sensor and
monitor of metabolic status. With the assistance of cyto-
chrome 
 
c
 
, cell death is initiated by the formation of a mac-
romolecular complex (the apoptosome), which utilizes ap-
optotic protease activating factor (APAF)-1 to mediate the
activation of caspase-9. The ‘extrinsic’ pathway transduces
the signals of extracellular ‘death ligands’ belonging to the
TNF superfamily (e.g., TNF-
 
a
 
, Fas ligand [FasL]/Apo1L/
CD95L, Trail/Apo2L, Apo3L). The binding of these
ligands to preassembled receptor complexes (3, 4) triggers
the activation of caspase-8 through the adapter molecule
Fas-associated death domain (FADD)/Mort1 (plus others
in some cases). Once the activation of initiator caspases oc-
curs by either of these two routes, the pathways converge
on the effector caspases (caspase-3 and caspase-7), which
are the proteolytic engines of cell death. Each of the two
pathways is modulated, as might be expected, by regulatory
polypeptides such as FLICE (FADD-like IL-1ß–converting
enzyme) inhibitory protein (cFLIP)/usurpin (‘extrinsic’
pathway) or Bcl-2 family members (‘intrinsic’ pathway),
and these molecules have been used to examine the rela-
tionship between the two pathways in vitro, and more re-
cently in vivo.
With the identification of these two distinct apoptotic
pathways, controversy raged as reports demonstrating that
Bcl-2 did not inhibit CD95-mediated apoptosis were
matched by an equal number of reports demonstrating that
it did (CD95, a.k.a. Fas/Apo1, being the archetypal extrin-
sic death receptor). Then, in 1998, the group led by Peter
Krammer and Marcus Peter (Scaffidi et al., reference 5) re-
ported the existence of two distinct cell types that utilize
distinct CD95 signaling pathways: type I cells undergo
CD95-mediated apoptosis without the involvement of mi-
tochondria, whereas type II cells require release of cyto-
chrome 
 
c
 
 from mitochondria in order for CD95 to exert its
apoptotic effects. At the molecular level, these two cell
types differ principally in the amount of caspase-8 re-
cruited to CD95 via the adapter molecule FADD/Mort1
to form the death-inducing signaling complex (DISC).
Whereas type I cells contain large amounts of DISC in re-
sponse to anti-CD95 antibodies, type II cells do not and
thus are dependent on stimulation of the intrinsic apop-
totic pathway to undergo cell death. These studies thus
could explain why the extrinsic apoptotic pathway was in-
sensitive to Bcl-2 overexpression in some cells (type I) but
sensitive to Bcl-2 overexpression in other cells (type II)
(6). The identification of Bid as the ‘go-between,’ trans-
mitting signals from the extrinsic to the intrinsic pathway,
provided a molecular basis for the cross-talk between the
two pathways (7, 8). Moreover, studies in vivo revealed
that hepatocytes had all of the characteristics of the Kram-
mer/Peter (reference 5) type II cell. Agonistic antibodies
to CD95 cause massive liver apoptosis and lethality in mice
due, at least in part, to liver failure. Overexpression of Bcl-2
in hepatocytes protects mice from anti-CD95–mediated
liver failure (9, 10). In addition, mice nullizygous for Bid,
the key protein involved in the cross-talk between the in-
trinsic and extrinsic pathways, are also resistant to the liver
failure that ensues after injection of anti-CD95 antibodies
(11). The absence of Bid, however, does not alter the sen-
sitivity of other cell types to anti-CD95 antibodies (e.g.,
thymocytes and fibroblasts). Taken together, these studies
support the existence of two distinct responders to CD95
stimulation, one dependent solely on the extrinsic pathway
and one dependent on both the extrinsic and intrinsic
pathways.
The idea that cross-talk exists between extrinsic and in-
trinsic apoptotic pathways in certain cell types is now
widely accepted; after all, cross-talk is a common theme in
the world of signal transduction. However, a small number
of groups remain cautious in accepting this notion. Andreas
Strasser and colleagues point out that many studies use ago-
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nistic antibodies to CD95 to stimulate the extrinsic path-
way. In their hands, these agonistic antibodies do not be-
have as the physiological form of the CD95L that, they
claim, is multimeric in nature (either membrane-associated
CD95L or cross-linked CD95L). While they do not ob-
serve significant hepatocyte apoptosis in the presence of
anti-CD95 antibodies, these cells are sensitive to the
CD95L when provided in a multimeric form (12). More-
over, the apoptotic cell death observed with the multimeric
ligand is not inhibited by overexpression of Bcl-2. In re-
sponse to this criticism, Schmitz et al. (Krammer group)
demonstrated that the differential sensitivity to Bcl-2 in
type I and type II cells is maintained when the extrinsic
pathway is stimulated by the CD95L rather than agonistic
antibodies to CD95 (13). It is important to note, however,
that the CD95L used in this study was trimeric rather than
multimeric and thus differs from that used in the studies by
Strasser and colleagues (14).
Figure 1. Extrinsic and intrinsic cell death signaling pathways. The majority of proteolytic cleavage events that manifest the apoptotic phenotype are
mediated by ‘effector’ caspases, such as caspase-3 and caspase-7, which become fully activated when the large and small subunits that are harbored within
the dormant proenzyme are liberated after endoproteolysis by upstream ‘initiator’ caspases, such as caspase-8 and caspase-9. The initiator caspases them-
selves are activated by autoproteolytic activation after facilitated oligomerization. In the extrinsic pathway, this occurs as a consequence of ligand binding
to ‘death receptor’ complexes, which leads to the recruitment of procaspase-8 via the adapter molecule FADD/Mort1. This pathway is modulated by the
availability of the molecular components (putative type I and type II cells differ in this regard) and dominant-negative regulators such as decoy receptors
and cFLIP/usurpin. For the majority of cell death stimuli, the intrinsic death signal is communicated through the mitochondrion by an unknown mech-
anism, which leads to several changes in the organelle, including the release of polypeptidic agents dangereux, such as cytochrome c and second mito-
chondria-derived activator of caspases (SMAC)/Diablo. This pathway is highly dependent on the stoichiometry of anti- versus proapoptotic Bcl-2 family
members. When enabled, caspase-9 activation occurs at the hands of the oligomerization mediator APAF-1, which requires cytochrome c for the appro-
priate conformation. SMAC/Diablo helps to cross another apoptosis checkpoint by sequestering inhibitors of apoptosis protein (IAPs), which would oth-
erwise block the actions of downstream effector caspases even in the presence of proteolytic maturation. Controversy surrounds the degree to which
cross-talk occurs between the extrinsic and intrinsic pathways in vivo. At a molecular level, this appears to occur via the proteolysis of BID, which nor-
mally serves an antiapoptotic role within the intrinsic pathway until it is truncated (to tBID) by caspase-8 (derived from the extrinsic pathway), where-
upon it promotes activation of the intrinsic pathway. In principle, signals from the extrinsic pathway may require the assistance of the intrinsic pathway,
for example, when the signal strength is weak or when the IAP barrier is high and the actions of SMAC/Diablo become necessary. 
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Is the nature of the ligand solely responsible for the dis-
crepant results obtained by the groups of Krammer/Peter
and colleagues and Strasser and colleagues in hepatocytes
and other type II cells? Moreover, and importantly, is the
multimeric CD95L actually a more physiological form of
the ligand? Would mice defective in Bid retain resistance to
hepatocellular injury in response to a more physiological
stimulus of the CD95 pathway?
The nature of the stimulus of the CD95 pathway does
not explain the fact that Strasser and colleagues do not ob-
serve significant cell death when type II cells are treated
with anti-CD95 antibodies or trimeric CD95L, whereas
Krammer and colleagues and several other groups do.
These discrepant results might be due to differences in the
‘tone’ of the intrinsic pathway (i.e., the sensitivity of the in-
trinsic pathway to apoptotic stimuli) and the tone of the in-
trinsic pathway might be influenced by the array of growth
factors and cytokines to which the cells are exposed. Vil-
lunger et al. elegantly illustrate this concept in the Septem-
ber 4 issue of this journal (15). They demonstrate that the
proinflammatory cytokine G-CSF stimulates the extracel-
lular signal–regulated kinase (ERK) pathway and inhibits
spontaneous apoptosis of granulocytes as well as apoptosis
induced by stimuli of the intrinsic pathway (etoposide and
doxorubicin) but not apoptosis induced by stimulation of
the extrinsic pathway with multimerized CD95L (granulo-
Figure 2. How apoptotic thresholding might
influence experimental outcome. Many possible
explanations may account for the differential
sensitivity of cells from the ‘Northern hemi-
sphere’ labs (e.g., Krammer/Peter) versus those
from the ‘Southern hemisphere’ (e.g., Strasser)
to CD95 stimulation (the Krammer/Peter labs
are located in Germany and the Strasser lab is in
Australia, hence the Northern and Southern
hemisphere references.). Herein is illustrated
one hypothesis. It assumes that most cell types
have an apoptotic threshold that, when
breached, results in apoptotic cell death. This
apoptotic threshold (represented by the red
plane) requires, say, 10 arbitrary apoptotic units
(which could be, among other things, a critical
mass of caspase catalytic activity). The ability of
a cell to cross this threshold depends on the
combined contributions of the extrinsic cell
death pathway (gray) and the fraction of the in-
trinsic pathway (blue) that can be engaged
through pathway cross-talk. Type I cells (first
bar), in both the Northern and Southern hemi-
spheres, harbor a very efficient DISC mecha-
nism that alone can contribute the necessary ap-
optotic units to breach the threshold. Thus,
regardless of the status of the intrinsic pathway,
and even if it is completely blocked by the pres-
ence of Bcl-2, the type I cell can muster the
necessary currency to engage the apoptotic ma-
chinery and die. Therefore, extrinsic and intrin-
sic pathways in type I cells appear independent
(assuming intrinsic does not talk to extrinsic). In
type II cells, DISC formation is weaker and the
extrinsic pathway depends more on contribu-
tions from the intrinsic pathway. These cells be-
have differently in the Northern hemisphere
versus the Southern hemisphere. In the North-
ern hemisphere, the combination of the extrin-
sic contribution and the fraction of the intrinsic
pathway that it is able to engage is sufficient for
apoptosis to proceed (second bar). Attenuation
of the intrinsic component, by Bcl-2 overex-
pression for example, reduces the total number
of apoptotic units to below the apoptotic
threshold and the cells survive. The extrinsic pathway, therefore, appears to be modulated by Bcl-2. In the Southern hemisphere, the number of available
apoptotic units that can be contributed by the intrinsic pathway may be lower. Thus, engagement of the extrinsic pathway with ligating CD95 (Fas/
Apo1) antibody or trimerized ligand is not sufficient to mediate passage across the apoptotic threshold on its own (third bar). With a more efficient stim-
ulus, mediated by multimerized CD95L, for example (fourth bar), a critical mass of the extrinsic pathway is enlisted to breach the apoptotic threshold, re-
gardless of the contribution from the intrinsic pathway. Cell death in this scenario is therefore insensitive to Bcl-2 overexpression. The differences ob-
served in the Northern and Southern hemispheres might therefore be explained by a combination of (a) the number of apoptotic units within the
intrinsic pathway that can be recruited by cross-talk from the extrinsic pathway (lower in the South) and (b) the strength of the apoptotic stimulus (ligat-
ing antibodies and trimerized CD95L being equivalent but weaker than multimerized CD95L). 
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cytes are resistant to weaker stimuli of the extrinsic path-
way such as agonistic antibodies to CD95 or trimerized
CD95L). Similarly, G-CSF prevents the death of granulo-
cytes stimulated by inhibitors of the mitogen-activated pro-
tein kinase (MAPK) pathway. Given that G-CSF does not
directly modulate the p38 MAPK pathway, Villunger et al.
suggest that both signal transduction pathways converge to
regulate the expression and/or activity of molecules that
interfere specifically with the intrinsic but not the extrinsic
pathway. They propose that the p38 MAPK and ERK
pathways inhibit the intrinsic apoptotic pathway by shifting
the delicate balance between pro- and antiapoptotic Bcl-2
family members, stimulating either the overexpression of
antiapoptotic Bcl-2 family members or the downregulation
of proapoptotic Bcl-2 family members (although Western
blot analyses failed to detect significant differences in the
expression of either pro- or antiapoptotic Bcl-2 family
members in response to G-CSF). This hypothesis is sup-
ported by the observation that overexpression of Bcl-2 acts
like G-CSF to protect granulocytes from spontaneous ap-
optosis as well as apoptosis stimulated by doxorubicin, cis-
platin, and p38 MAPK inhibitors but not from multimeric
CD95.
Although the mechanism by which the complex inter-
play between the signal transduction pathways and the in-
trinsic apoptotic pathway remains ill defined, this interplay
is no less important and might be responsible for the differ-
ences in sensitivity of cells to anti-CD95 antibodies ob-
served by Strasser and colleagues and Krammer and col-
leagues, as illustrated in Fig. 2. Alterations in the tone of
the intrinsic apoptotic pathway may affect the ability of
cells to respond to suboptimal stimulation of the extrinsic
pathway in type II cells using anti-CD95 antibodies or tri-
meric CD95L (type I cells, for reasons that remain obscure,
appear to support productive formation of the DISC
(CD95, FADD/MORT1, caspase-8), irrespective of the
strength of the stimulus). Type II cells, exposed to cyto-
kines or growth factors that activate the signal transduction
pathways and increase the resistance of mitochondria to the
cytochrome 
 
c
 
–releasing effects caused by cleavage of Bid,
might behave as reported by Huang et al. (Strasser group;
reference 12). These cells survive a weak CD95 stimulus
(anti-CD95 antibodies or trimeric CD95L) that is depen-
dent on the intrinsic pathway but die in the presence of a
strong CD95 stimulus (e.g., multimeric CD95L) that is not
dependent on the intrinsic pathway. In contrast, cells main-
tained in an environment impoverished in cytokines/
growth factors might behave as reported by Scaffidi et al.
(Krammer group; reference 5). These cells exhibit a proap-
optotic response to a weak CD95 stimulus that is inhib-
itable by Bcl-2 overexpression or Bid deficiency.
Do distinct apoptotic pathways exist when the tone of
the intrinsic pathway is shifted toward an antiapoptotic
state, whereas cross-talk exists between intrinsic and extrin-
sic pathways when the tone of the intrinsic pathway is
shifted toward a proapoptotic state? This hypothesis would
certainly reconcile the discrepancies observed between the
groups of Krammer/Peter and colleagues and Strasser and
colleagues. There are, however, other explanations as well
that will no doubt emerge as the literature in this area
evolves. But at least some things are clear. The existence of
at least two distinguishable cell death–signaling pathways
has been well established (extrinsic and intrinsic), and the
identification of the major molecular components of these
pathways provides a framework for predicting the circum-
stances under which each becomes engaged to initiate ap-
optosis. Similarly, and more recently, the discovery of mol-
ecules that betray the activities of one pathway to the other
(such as Bid) account for the apparent cross-talk that many
laboratories have observed, thus providing other obvious
experiments to perform. Next comes context, and it is the
in vivo circumstances that may largely dictate whether the
two pathways remain isolated or cooperate in their tasks
(e.g., cell type, signal type and strength, endogenous apop-
totic tone, etc.). As with many biochemical pathways be-
fore it, ambiguity will reign supreme in apoptosis signaling
before clarity emerges.
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